Blood-based diagnostic assays for alzheimer's disease
AssigneeCassava Sciences, Inc.
InventorsIan Pike, Michael Bremang, George Thornton
Life of this patent
Estimating the term…
Abstract
The invention relates to sets of biomarkers and methods of use thereof for diagnosing, staging, treating, and assessing the response of a treatment for neurocognitive disorders characterised by tau toxicity, such as Alzheimer’s disease.
Claims20
A biomarker panel comprising one or more phosphorylated peptides obtained from in vitro digestion of a Filamin A protein having the polypeptide sequence of SEQ ID NO:
- 1.
The biomarker panel of claim 3, wherein the neurological disease is Alzheimer’s disease.
A biomarker panel, wherein the biomarker panel comprises a plurality of phosphorylated peptides, wherein each phosphorylated peptide is a fragment of SEQ ID NO:1 and comprises a phosphorylation site at a position corresponding to serine 2143, 2152, and/or 2180 of SEQ ID NO:
- 1.
A biomarker panel, comprising a plurality of phosphorylated peptides, each having the sequence of SEQ ID Nos:
- 2-12 and being phosphorylated at a position corresponding to serine 2143, 2152, and/or 2180 of SEQ ID NO:
- 1.
A biomarker panel, comprising at least 2, 3, 4, 5, 6, 7, 8, 9, or 10 different phosphorylated peptides, each being phosphorylated at a site corresponding to serine residue 2143, 2152 and/or 2180 of SEQ ID NO:
- 1.
A biomarker panel, comprising:
- (i) one or more peptides obtained from in vitro digestion of Filamin A using a protease or combination of proteases, wherein each of the one or more peptides comprises an amino acid sequence present in SEQ ID NO:1;
- and (ii) one or more peptides obtained from in vitro digestion of one or more, optionally two or more of the proteins listed in Tables 1-4.
A method for the diagnosis/prognosis of a neurological disorder, comprising:
- obtaining a bodily fluid or tissue sample from a subject;
- digesting one or more proteins in the bodily fluid or tissue sample with one or more proteases;
- and
- detecting and/or measuring the level of one or more peptides produced from the digestion, using mass spectrometry, wherein the one or more peptides are obtained from in vitro digestion of one or more of the proteins listed in Tables 1-4.
A method for monitoring the progression of a neurological disorder, comprising:
- (a) obtaining a bodily fluid or tissue sample from a subject at a first time point;
- (b) digesting one or more proteins in the bodily fluid or tissue sample with one or more proteases;
- (c) detecting and/or measuring the level of one or more peptides produced from the digestion, using mass spectrometry, wherein the one or more peptides are obtained from in vitro digestion of one or more of the proteins listed in Tables 1-4;
- and
- (d) repeating steps (a)-(c) at a second time point.
Dependencies are inferred from the claim text.